Haploidentical SCT in patients with high risk AML: experience of one center.

Patients with high risk AML have short duration of remission. Availability of a donor is “corner stone” for best transplant results. Median time for activation a donor from the international register is several months. Choosing a haploidentical donor could be good alternative when matched related donor is unavailable and waiting for MUD too long.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Dmitriy Motorin, Renat Badaev, Darina Zammoeva, Larisa Girshova, Diana Babenetskaya, Natalya Ilyina, Tatyana Silina, Yuliya Alexeeva, Vladimir Ivanov, Andrey Zaritskiy Source Type: research